Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
about
The basal transcription machinery as a target for cancer therapyKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaAcute Kidney Injury in Hematopoietic Stem Cell Transplantation: A ReviewImpact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerThe history and future of targeting cyclin-dependent kinases in cancer therapy.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Onco-nephrology: AKI in the cancer patient.Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapyClinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaWhat do we do with chronic lymphocytic leukemia with 17p deletion?Transcription inhibition as a therapeutic target for cancerAlvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.Tumor Lysis Syndrome in Patients with Hematological Malignancies.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.Renal involvement in chronic lymphocytic leukemia
P2860
Q21246017-2F5F6642-E9A4-424D-8452-536920C30070Q26781895-BAA09894-E0F0-4EAD-B1AF-406314698D61Q28074157-46FECBE1-35B8-4528-B454-1988C14C1740Q33717615-E14673B3-9369-4882-A8CF-8EFB61D7D2E5Q34460347-5D53FBB6-B4AE-4B3A-9E07-BCB3F8761893Q35920657-30E81E8F-3790-4A75-9FB6-555F6D74DBE5Q36000944-F4080237-BC1C-4840-9CA8-5FF6086B9027Q36003724-63451FE5-6291-4B5C-BAF3-F63AFA411FFAQ36294351-13098679-DAAF-46F7-88C4-DA61D112FE9DQ36709001-382D59F1-2008-4339-8F6B-3BE53F2FABCFQ37168430-085317D4-7F14-4885-96FC-68DB047EE7B9Q37199802-25FDD602-D699-4197-8692-D74549A0A96FQ37354482-AC6900E7-F817-49A6-807D-46DD86E63E92Q37602430-B5D1D843-A161-408D-B720-EAF52A0E581FQ38063170-026132E2-E53F-4D3F-BDCB-1CDF89709E72Q38161381-0EE28FED-CAF2-4078-924A-0826B567BBBFQ38783064-06C0D5CD-32FD-4444-A4A9-665C2DACBD6CQ46949121-DCB4B039-3922-482F-971D-D3C58ED5F747Q47887134-E0B587A7-7537-43A4-99F6-C358B44336A0Q57053852-2D6CDAAF-796E-4426-9261-044B3E46440F
P2860
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@ast
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@en
type
label
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@ast
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@en
prefLabel
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@ast
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@en
P2093
P2860
P356
P1433
P1476
Risk factors for tumor lysis s ...... inase inhibitor, flavopiridol.
@en
P2093
A J Johnson
A S Ruppert
J A Woyach
L Andritsos
P2860
P2888
P304
P356
10.1038/LEU.2011.109
P577
2011-05-24T00:00:00Z